5356

Novo Nordisk’s sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024Novo Nordisk’s sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Novo Nordisk’s sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Bagsværd, 5 February 2025 - Financial report for the period 1 January 2024 to 31 December 2024      …

3 months ago
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherenceNovo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in…

3 months ago
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to closeNovo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S’s…

5 months ago
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to closeNovo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S’s…

5 months ago